Thomas Doyle
Comptroller/Controller/Auditor at KURA ONCOLOGY, INC.
Net worth: 1 M $ as of 2024-03-30
Profile
Thomas Doyle's career history includes the following positions:- Senior Vice President-Finance & Accounting at Kura Oncology, Inc. (2022 - Present)Former Jobs:- Director-Internal Audit, Head-R&D Finance at Bausch Health Americas, Inc. (2004 - 2008)- Director-Revenue & Cost Accounting at ISTA Pharmaceuticals, Inc. (2008 - 2011)- Controller at Avid Bioservices, Inc.- Vice President-Finance at Zogenix, Inc. (2013 - 2021)Education:- Undergraduate degree from San Diego State University- MBA from California State University-San Marcos.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
KURA ONCOLOGY, INC.
0.06% | 2024-01-28 | 48,593 ( 0.06% ) | 1 M $ | 2024-03-30 |
Thomas Doyle active positions
| Companies | Position | Start |
|---|---|---|
| KURA ONCOLOGY, INC. | Comptroller/Controller/Auditor | 2022-02-06 |
Former positions of Thomas Doyle
| Companies | Position | End |
|---|---|---|
| ZOGENIX, INC. | Corporate Officer/Principal | 2021-05-31 |
ISTA Pharmaceuticals, Inc.
 ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Comptroller/Controller/Auditor | 2011-02-28 |
Bausch Health Americas, Inc.
 Bausch Health Americas, Inc. Pharmaceuticals: MajorHealth Technology Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ. | Comptroller/Controller/Auditor | 2008-11-30 |
| AVID BIOSERVICES, INC. | Comptroller/Controller/Auditor | - |
Training of Thomas Doyle
| San Diego State University | Undergraduate Degree |
| California State University-San Marcos | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| AVID BIOSERVICES, INC. | Health Technology |
| KURA ONCOLOGY, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Bausch Health Americas, Inc.
Bausch Health Americas, Inc. Pharmaceuticals: MajorHealth Technology Bausch Health Americas, Inc. manufactures and distributes pharmaceutical products. The company was founded on November 29, 2011 and is headquartered in Bridgewater, NJ. | Health Technology |
ISTA Pharmaceuticals, Inc.
ISTA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology ISTA Pharmaceuticals, Inc. was incorporated as Advanced Corneal Systems, Inc. in California in February 1992 to discover, develop, and market new remedies for diseases and conditions of the eye. In March 2000, the company changed its name to ISTA Pharmaceuticals, Inc. It reincorporated, in Delaware, in August 2000. BROMDAY, BEPREVE, ISTALOL, VITRASE, XIBROM (bromfenac ophthalmic solution), XIBROM, T-PRED, PROLENSA, BEPOSONE, BEPOMAX, ISTA, ISTA Pharmaceuticals, Inc. and the ISTA logo are its trademarks, either owned or under license. Ista is commercial-stage, multi-specialty pharmaceutical company, which develops, markets, and sells its own products in the United States and Puerto Rico. Its products are intended to treat allergy and serious diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye, and ocular and nasal allergies. | Health Technology |
Zogenix, Inc.
 Zogenix, Inc. Pharmaceuticals: MajorHealth Technology Zogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. | Health Technology |
- Stock Market
- Insiders
- Thomas Doyle
